RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
A user inquired about Cipla Tugain Men, a topical solution containing Minoxidil 5% and Finasteride 0.1%, noting its less greasy texture and good price. Responses suggest it's similar to other products with the same ingredients, questioning the effectiveness of additional components.
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
Topical finasteride is believed to reduce scalp DHT more than oral forms, but its effectiveness is questioned due to inconsistent application and absorption. Oral finasteride is considered more effective because it consistently reduces systemic DHT, ensuring more reliable results.
A user experienced hair loss due to a folic acid deficiency and saw hair regrowth after taking a folic acid supplement. They advise checking for a folic acid deficiency before spending money on other treatments.
A 24-year-old has seen no progress in hair loss treatment after a year using topical finasteride 0.3%, minoxidil 0.6%, and 0.5mg dutasteride daily. They experienced side effects from oral minoxidil and are seeking advice on next steps without adding RU58841.
Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.
Obtaining treatments for hair loss that are not approved in one's own country, such as pyrilutamide or GT20029. It was suggested to use a middleman to get it, but there is the risk of getting low quality or fake products.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.